David W. Kang

621 total citations
34 papers, 449 citations indexed

About

David W. Kang is a scholar working on Cell Biology, Molecular Biology and Hematology. According to data from OpenAlex, David W. Kang has authored 34 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cell Biology, 9 papers in Molecular Biology and 8 papers in Hematology. Recurrent topics in David W. Kang's work include Proteoglycans and glycosaminoglycans research (19 papers), Platelet Disorders and Treatments (8 papers) and Fibroblast Growth Factor Research (5 papers). David W. Kang is often cited by papers focused on Proteoglycans and glycosaminoglycans research (19 papers), Platelet Disorders and Treatments (8 papers) and Fibroblast Growth Factor Research (5 papers). David W. Kang collaborates with scholars based in United States, Australia and United Kingdom. David W. Kang's co-authors include Monica L. Zepeda, Robert J. Gregory, Anna L. Remen, Subhdeep Virk, Marie A. Printz, Michael J. LaBarre, Robert Connor, Barbara Blouw, Markku Tammi and Mark E. Davis and has published in prestigious journals such as PLoS ONE, Cancer Research and Advanced Drug Delivery Reviews.

In The Last Decade

David W. Kang

29 papers receiving 401 citations

Peers

Countries citing papers authored by David W. Kang

Since Specialization

Citations

This map shows the geographic impact of David W. Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Kang more than expected).

Fields of papers citing papers by David W. Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Kang. The network helps show where David W. Kang may publish in the future.

Co-authorship network of co-authors of David W. Kang

This figure shows the co-authorship network connecting the top 25 collaborators of David W. Kang. A scholar is included among the top collaborators of David W. Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. Kang. David W. Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Preclinical Testing of a Rapid, High-Volume, Auto-Injector for Subcutaneous Administration with Recombinant Human Hyaluronidase 2025 ·AAPS PharmSciTech ·Robert Connor, (unknown), David W. Kang	1
2	Machine learning-integrated biomimetic electronic noses: Future perspectives 2025 ·Microchemical Journal ·(unknown), (unknown), Sang Won Lee, (unknown), David W. Kang, (unknown), Han-Jeong Hwang, (unknown), Gyudo Lee	6
3	A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidase 2025 ·Drug Delivery and Translational Research ·David W. Kang, Robert Connor, (unknown), (unknown), (unknown), (unknown), Michael J. LaBarre	0
4	The 96‐Puddle Paper Plate as a Versatile Lab‐on‐Paper Platform 2025 ·Small Methods ·(unknown), (unknown), David W. Kang, (unknown), Sang Won Lee, Insu Park, Gyudo Lee	1
5	Recent Advances in Loop-Mediated Isothermal Amplification (LAMP) for On-Site Virus Detection 2025 ·Journal of Sensor Science and Technology ·David W. Kang, (unknown), (unknown), (unknown), Gyudo Lee	0
6	The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies 2024 ·Journal of Controlled Release ·(unknown), David W. Kang, Daniel C. Maneval, (unknown), Michael J. LaBarre, Marie A. Printz	1
7	Investigating the contribution of hyaluronan to the breast tumour microenvironment using multiparametric MRI and MR elastography 2023 ·Molecular Oncology ·(unknown), Jin Li, (unknown), Jessica K.R. Boult, J. D. Sullivan, Craig Cummings, Barbara Blouw, David W. Kang, Ralph Sinkus, Jeffrey C. Bamber, Yann Jamin, Simon P. Robinson	4
8	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models 2021 ·Journal of Experimental & Clinical Cancer Research ·Lavinia Morosi, (unknown), Paolo Ubezio, Ilaria Fuso Nerini, Lucia Minoli, Luca Porcu, Nicolò Panini, (unknown), Barbara Blouw, David W. Kang, Enrico Davoli, Massimo Zucchetti, Maurizio D’Incalci, Roberta Frapolli	47
9	Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer 2021 ·PLoS ONE ·David W. Kang, Beate Bittner, Barry J. Sugarman, Monica L. Zepeda, Marie A. Printz	9
10	Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans 2021 ·AAPS PharmSciTech ·(unknown), Robert Connor, David S. Collins, David W. Kang	13
11	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers 2020 ·Current Therapeutic Research ·Marie A. Printz, Samuel S. Dychter, (unknown), (unknown), Barry J. Sugarman, Monica L. Zepeda, (unknown), David W. Kang, Daniel C. Maneval	17
12	A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration 2020 ·Dermatology and Therapy ·Robert Connor, Barbara Blouw, (unknown), Kelly Chen, Chun‐Mei Zhao, David W. Kang	2
13	Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats 2019 ·Journal of Controlled Release ·(unknown), Orlagh M. Feeney, Tri‐Hung Nguyen, (unknown), David W. Kang, (unknown), Michelle P. McIntosh, Christopher J. H. Porter	19
14	Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma 2018 ·Clinical Cancer Research ·Jianbo Cao, Stephen Pickup, Cynthia Clendenin, Barbara Blouw, Hoon Choi, David W. Kang, Mark Rosen, Peter J. O’Dwyer, Rong Zhou	23
15	Single-Molecule Unbinding Forces between the Polysaccharide Hyaluronan and Its Binding Proteins 2018 ·Biophysical Journal ·Fouzia Bano, Markku Tammi, David W. Kang, Edward N. Harris, Ralf P. Richter	26
16	Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein 2013 ·Journal of Pharmacological and Toxicological Methods ·David W. Kang, (unknown), (unknown), Jennifer M. Anderson, Monica L. Zepeda	23
17	Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model 2012 ·Drug Delivery and Translational Research ·David W. Kang, (unknown), (unknown), Fred H. Drake, Monica L. Zepeda	20
18	A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. 2008 ·Psychotherapy ·Robert J. Gregory, (unknown), David W. Kang, Anna L. Remen, (unknown), (unknown), Subhdeep Virk	96
19	An Open-Label Study to Evaluate Switching from an SSRI or SNRI to Tiagabine to Alleviate Antidepressant-Induced Sexual Dysfunction in Generalized Anxiety Disorder 2007 ·Annals of Clinical Psychiatry ·Thomas L. Schwartz, (unknown), Adam Keller Ashton, David W. Kang, (unknown), Mark Chilton, (unknown)	6
20	Recombinant adenovirus‐p21 attenuates proliferative responses associated with excessive scarring 2005 ·Wound Repair and Regeneration ·Danling Gu, Isabella Atencio, David W. Kang, (unknown), C. M. Iqbal Ahmed, Alina Levy, (unknown), Monica L. Zepeda	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact